Role of Inflammation in Psychiatric Disorders

  • Sang Won Jeon
  • Ho-kyoung Yoon
  • Yong-Ku KimEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1192)


Psychiatric disorders are too multifactorial to be defined as a primarily inflammatory disorder, and increased inflammatory response is not specific to mental disorder only. Numerous factors are involved in neuroinflammation, and there also are many confounding variables, making it difficult to obtain consistent outcomes. Therefore, it is necessary to specify genetic, physiological, and epidemiological attributes of particular population groups vulnerable to inflammatory response as well as the disease subtypes. As of now, definitive inflammatory markers for psychiatric disorders have not been identified, but they could be very useful in patients with minimal vulnerability. In addition, it is possible to use inflammatory markers as depression biomarkers in subtypes of depression, which can serve as bases to develop medications to treat the disorder.


Inflammation Neuroinflammation Cytokine Psychiatric disorder Depression Medication 


  1. 1.
    Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:277–86.PubMedCrossRefGoogle Scholar
  2. 2.
    Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Furtado M, Katzman MA. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res. 2015;229(1–2):37–48.PubMedCrossRefGoogle Scholar
  4. 4.
    Kim YK, Na KS, Myint AM, Leonard BE. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:277–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep. 2011;13(6):467–75.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol. 2005;18(1):41–78.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Marques AH, Cizza G, Sternberg E. Brain-immune interactions and implications in psychiatric disorders. Braz J Psychiatry. 2007;29(Suppl 1):S27–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med. 2003;35(1):2–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Christmas DM, Potokar J, Davies SJ. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neuropsychiatr Dis Treat. 2011;7:431–9.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Maes M, Stevens W, DeClerck L, Bridts C, Peeters D, Schotte C, et al. Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio. Acta Psychiatr Scand. 1992;86(6):423–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, et al. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J Affect Disord. 1998;49(3):211–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Leonard BE, Myint A. Inflammation and depression: is there a causal connection with dementia? Neurotox Res. 2006;10(2):149–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci. 2013;14:135–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26(5):643–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry. 2009;14(12):1095–104.PubMedCrossRefGoogle Scholar
  18. 18.
    Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009;65(4):296–303.PubMedCrossRefGoogle Scholar
  19. 19.
    Dean B, Tawadros N, Scarr E, Gibbons AS. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord. 2010;120(1–3):245–8.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Glover AT, Shaw SM, Williams SG, Fildes JE. Can inflammation be an independent predictor of depression? Brain Behav Immun. 2010;24(2):173 author reply 4–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–57.PubMedCrossRefGoogle Scholar
  22. 22.
    Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83(5):495–502.PubMedCrossRefGoogle Scholar
  23. 23.
    de Beaurepaire R. Questions raised by the cytokine hypothesis of depression. Brain Behav Immun. 2002;16(5):610–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Weizman R, Laor N, Podliszewski E, Notti I, Djaldetti M, Bessler H. Cytokine production in major depressed patients before and after clomipramine treatment. Biol Psychiatry. 1994;35(1):42–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R. Low levels of circulating inflammatory cytokines–do they affect human brain functions? Brain Behav Immun. 2002;16(5):525–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand. 1998;97(4):309–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Ravindran AV, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom Med. 1998;60(3):283–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Jeon SW, Kim YK. Neuroinflammation and cytokine abnormality in major depression: cause or consequence in that illness? World J Psychiatry. 2016;6(3):283–93.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Jeon SW, Kim YK. Inflammation-induced depression: its pathophysiology and therapeutic implications. J Neuroimmunol. 2017;313:92–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Sigalas PD, Garg H, Watson S, McAllister-Williams RH, Ferrier IN. Metyrapone in treatment-resistant depression. Ther Adv Psychopharmacol. 2012;2(4):139–49.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61(12):1235–44.PubMedCrossRefGoogle Scholar
  32. 32.
    Cardoso C, Kingdon D, Ellenbogen MA. A meta-analytic review of the impact of intranasal oxytocin administration on cortisol concentrations during laboratory tasks: moderation by method and mental health. Psychoneuroendocrinology. 2014;49:161–70.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30(4):297–306.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 2013;263(5):367–77.PubMedCrossRefGoogle Scholar
  35. 35.
    Jeon SW, Kim YK. The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. J Inflamm Res. 2018;11:179–92.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O’Neil A, et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 2013;11:74.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol. 2014;29(3):216–23.CrossRefGoogle Scholar
  38. 38.
    Ekdahl CT. Microglial activation-tuning and pruning adult neurogenesis. Front Pharmacol. 2012;3:41.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Calder PC. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3–5):101–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol. 2012;32(1):61–4.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Jazayeri S, Tehrani-Doost M, Keshavarz SA, Hosseini M, Djazayery A, Amini H, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. 2008;42(3):192–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Seo HJ, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, et al. Curcumin as a putative antidepressant. Expert Rev Neurother. 2015;15(3):269–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord. 2014;167:368–75.PubMedCrossRefGoogle Scholar
  45. 45.
    Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014;28(4):579–85.PubMedCrossRefGoogle Scholar
  46. 46.
    Levine J, Cholestoy A, Zimmerman J. Possible antidepressant effect of minocycline. Am J Psychiatry. 1996;153(4):582.PubMedGoogle Scholar
  47. 47.
    Mello BS, Monte AS, McIntyre RS, Soczynska JK, Custodio CS, Cordeiro RC, et al. Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J Psychiatr Res. 2013;47(10):1521–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open. 2012;2(1):e000643.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Psychiatry, Kangbuk Samsung HospitalSungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Department of PsychiatryCollege of Medicine, Korea University, Ansan HospitalAnsan-si, Gyeonggi-doRepublic of Korea

Personalised recommendations